Information on 
Informationen zu 
Informaciones sobre
A propos du
Informazioni suAbout Us / Corporate Strategy
The corporate strategy of SpePharm is based upon acquiring or obtaining under license the European rights to quality and innovative products for hospitals and specialists within a limited number of therapeutic fields. The initial focus is on products for oncology, hematology, critical and supportive care. SpePharm may also consider other segments where medical and commercial synergies can be developed, such as niche indications, orphan drugs and low-volume products of high medical value and that have limited competition. A further key element of our strategy is the development of valued relationships with hospital physicians, and other hospital staff that are close to patients.
SpePharm is rapidly developing into a pan-European specialty pharmaceutical company active in the hospital and specialist segments by seeking to in-license or acquire:
- innovative products at pre-registration or registration stage, to be launched throughout Europe; and
- already marketed, non-core products from larger pharmaceutical companies.
SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe.